NBIX Neurocrine Biosciences, Inc.
Healthcare$157.47+0.00%OpenMarket Cap: $15.83B
As of 2026-05-26
Valuation
P/E (TTM)
27.45
PEG
0.68
P/B
4.62
P/S
5.08
EV/EBITDA
18.04
DCF Value
$451.44
FCF Yield
5.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.2%
Operating Margin
25.2%
Net Margin
21.6%
ROE
21.6%
ROA
13.6%
ROIC
13.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $814.5M | 98.3% | $186.0M | $197.9M | $— | — |
| Q4 null | $805.5M | 97.8% | $210.9M | $153.7M | $— | — |
| FY null | $2.86B | 98.2% | $619.1M | $478.6M | $— | — |
| Q3 null | $794.9M | 98.2% | $239.0M | $209.5M | $— | — |
| Q2 null | $687.5M | 98.4% | $145.6M | $107.5M | $— | — |
| Q1 null | $572.6M | 98.4% | $23.6M | $7.9M | $— | — |
| Q4 null | $627.7M | 98.5% | $142.0M | $103.1M | $— | — |
| FY null | $2.36B | 98.6% | $570.5M | $341.3M | $— | — |
| Q3 null | $622.1M | 98.7% | $183.8M | $129.8M | $— | — |
| Q2 null | $590.2M | 98.4% | $145.4M | $65.0M | $— | — |
| Q1 null | $515.3M | 98.5% | $99.3M | $43.4M | $— | — |
| Q4 2023 | $515.2M | 98.4% | $150.3M | $147.7M | $1.44 | — |